QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Near Add Your Location

Sorting 26 by

UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Norton Cancer Institute (St. Matthews)
St. Matthews Campus
Louisville, KY
  • Accepting patients
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Accepting patients
Rutgers Cancer Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, NJ
  • Accepting patients
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
111 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.